Adtran launches new FSP 3000 OLS to unlock the coherent optical edge
25.5.2023 15:00:00 EEST | Business Wire | Press release
Adtran today launched its FSP 3000 Edge OLS, an open line system designed for the new generation of coherent edge access, aggregation and metro networks. It enables operators to efficiently address soaring bandwidth demand from mobile, broadband and enterprise applications by leveraging the latest coherent pluggable technology in this cost-sensitive part of the network. The FSP 3000 Edge OLS has been specifically engineered for the use of coherent transmission at the optical edge, including the recently introduced Coherent 100ZR, as well as 400ZR optics. By utilizing power-optimized wavelength broadcasting technology and a gridless architecture, the solution enables a simple and affordable optical layer with compact and flexible nodes that can transport any coherent signal and baud rate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005466/en/
Adtran’s FSP 3000 Edge OLS will help operators deploy coherent optical edge networks in the most effective way possible. (Graphic: Business Wire)
“At OFC, we showcased our world-first QSFP28 Coherent 100ZR, bringing robust, efficient and simple coherent technology to the edge of the network. Now we’re complementing this innovative transceiver with an OLS optimized for the cost-efficient transport of coherent technology at the optical edge. Providing maximum performance, it meets all critical demands of edge aggregation networks, including scalability, compact design, low power consumption, operational simplicity and extended temperature operation for outdoor deployment,” said Christoph Glingener, CTO at Adtran. “Our pioneering work at the network edge is creating whole new opportunities for service providers.”
The Adtran FSP 3000 Edge OLS is an open line system engineered to help operators roll out coherent optical edge networks in the most cost-effective and flexible way possible. With ZR-optimized technology for minimal insertion loss, the new OLS enables the use of ZR coherent optics at the optical edge in multiple use cases, including linear, hub-and-spoke or tree topologies. With its modular design, it empowers users to mix and match elements to create a solution that meets their exact needs. What’s more, the Adtran FSP 3000 Edge OLS facilitates the development of a compact and efficient optical layer with low-power nodes that require minimal space and can function in an extended temperature range. This enables deployment in outdoor environments, such as street cabinets.
“Our FSP 3000 Edge OLS offers a major boost to operators looking for an affordable way to tackle relentless growth in data traffic. Low-cost yet highly flexible, it can scale to transparently accommodate any line speed or baud rate. Now there’s a clear route to deploying an optical layer that leverages coherent transport technology, including 100ZR and 400ZR optics, and meets the stringent requirements of the new optical edge,” commented Henning Hinderthür, VP of product line management, Optical Networks at Adtran. “Our FSP 3000 Edge OLS harnesses advanced wavelength broadcast technology for new levels of power and cost efficiency. It’s also ready to be deployed anywhere from central offices to street furniture.”
Further details on Adtran’s FSP 3000 Edge OLS are available in these slides.
A supporting product video is available to watch.
A solution brief can also be downloaded.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005466/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom